Patents Assigned to Board of Regents, The University of Texax System
  • Antibody conjugate kits for selectively inhibiting VEGF
    Patent number: 6416758
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 9, 2002
    Assignee: Board of Regents, The University of Texax System
    Inventors: Philip E. Thorpe, Rolf A. Brekken